🔗 Share this article

Given that the US continues making sweeping adjustments to its vaccine guidelines, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by expressing skepticism about COVID-19 vaccinations in the global health crisis and has focused upon alleged deaths following COVID-19 vaccination in her short tenure at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Immunization Program

Health officials had intended to reveal radical revisions to the childhood vaccine schedule in December, bringing the US with Denmark’s national calendar, according to reports – a significant shift that would place the US at odds with much of the global community with insufficient data for benefit. This reveal has been postponed until the new year.

Rather than Vinay Prasad, Dr. Høeg is listed to address the audience at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth appointee to run the center this year.

Consolidating Power at the FDA

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for halting some childhood vaccine recommendations in the US in order to be more like Denmark, a society with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

To date public appearances, she has continued to focus on immunizations – traditionally the responsibility of Prasad, director of the FDA’s CBER – as opposed to medication approval.

Questions Over Background

Dr. Høeg has no apparent experience in pharmaceutical research, regulation or leadership, which has been customary for previous heads of the biologics center. She has worked at the FDA as a senior adviser to the agency head and CBER since spring.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in leading a large organization. She lacks background in industry regulation.”

Former directors of CBER would “be deeply familiar with legal statutes and the research of medication creation”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that previous people who led CBER have had.”

This division has an vast portfolio at the FDA, she emphasized.

“The public just pays attention on the new drug program, but the generic drug division clears thousands of generic medications. There’s a biosimilars program, OTC medication office and so forth, and every single one have to be looked after,” Dr. Woodcock explained. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major management aspect to the role, which oversees in excess of 5,000 employees. “It is a enormous management job, if you perform it correctly,” the former official said.

Response and Contentious Initiatives

In response to concerns about Høeg’s qualifications and whether this assignment indicates greater collaboration among regulatory chiefs on vaccines, a representative responded that the “concerns rely on inaccurate premises”.

“This background aligns with the responsibilities of her role,” the official explained, pointing to the months Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s new fast-track approval initiative, a controversial one-day medication authorization process that allegedly concerned her preceding directors. “By what process are these drugs being picked for this expedited pathway? Who is making the choices?” Howard questioned. “There is a lot of secrecy going on at the agency right now.”

Overall, he remarked, “the Food and Drug Administration appears to be shifting towards less stringent oversight of pharmaceuticals, aside from immunizations.”

Public Track Record on Vaccines

With vaccines, Dr. Høeg has a more documented, if concerning, track record, critics said. She authored a study using unverified volunteer-provided data to determine the frequency of heart inflammation after COVID-19 vaccination. She counseled the Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are more dangerous than they are.

Included in her “wish list” for the new government encompassed altering guidelines for recently developed shots and ending “non-essential” vaccines, she stated after the election on a podcast. At the agency, Dr. Høeg has reportedly proposed preventing adolescent males from getting Covid vaccines.

“She’s an all-around ideologue who commences with her beliefs and works backwards to fit the evidence in a extremely deceptive, fraudulent fashion,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg aligned with other skeptics, {like|